



Ziconotide

Revised: May 15, 2023.

CASRN: 107452-89-1

Drug Levels and Effects

Summary of Use during Lactation

No information is available on the clinical use of ziconotide during breastfeeding. Ziconotide is usually not detectable or barely detectable in plasma after intrathecal administration, and because it is a peptide with a molecular weight of 2639 Daltons, the amount in milk is likely to be very low. It is also likely to be partially destroyed in the infant's gastrointestinal tract and absorption by the infant is probably minimal. If ziconotide is required by the mother, it is not a reason to discontinue breastfeeding. Breastfed infants should be monitored for sedation, which may result in respiratory depression or feeding problems.

Drug Levels

Maternal Levels. Relevant published information was not found as of the revision date.

Infant Levels. Relevant published information was not found as of the revision date.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

Substance Identification

Substance Name

Ziconotide

Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.

Attribution Statement: LactMed is a registered trademark of the U.S. Department of Health and Human Services.

CAS Registry Number

107452-89-1

Drug Class

Breast Feeding

Lactation

Milk, Human

Analgesics, Non-Narcotic

Calcium Channel Blockers

Neuroprotective Agents